Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Actinium Pharmaceuticals
- Registration Number
- NCT03932318
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 17
- Registration Number
- NCT03900884
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 7
- Registration Number
- NCT03886649
- Locations
- 🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭Hôpitaux Universitaires de Genève, Genève, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03884972
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Brian Druker
- Target Recruit Count
- 50
- Registration Number
- NCT03874052
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 71
- Registration Number
- NCT03873857
- Locations
- 🇷🇺
Clinical Medico-Sanitary Unit #1 /ID# 212364, Perm, Russian Federation
🇷🇺Republican Hospital #1 - National Center of Medicine of Sakha (Yakutia) /ID# 212371, Yakutsk, Russian Federation
🇷🇺Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 212372, Sankt-Peterburg, Russian Federation
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 14
- Registration Number
- NCT03873493
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center /ID# 207746, Houston, Texas, United States
🇬🇧Oxford University Hospitals NHS Foundation Trust /ID# 211264, Oxford, Oxfordshire, United Kingdom
🇳🇱Maxima Medisch Centrum /ID# 207989, Eindhoven, Netherlands
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 23
- Registration Number
- NCT03872180
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory Johns Creek Hospital, Johns Creek, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.